Video Experimental Relacionado
Updated: Jul 5, 2026
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Efecto de un curso de 6 semanas de péptido 1 similar al glucagón en el control glucémico, la sensibilidad a la
Mette Zander1, Sten Madsbad, Jan Lysgaard Madsen
1Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark. M.Zander@dadlnet.dk
Lancet (London, England)
|March 19, 2002
Resumen
El tratamiento continuo con el péptido 1 similar al glucagón (GLP-1) mejoró significativamente el control glucémico y la función de las células beta en pacientes con diabetes tipo 2. Este estudio piloto sugiere que la GLP-1 es un agente terapéutico prometedor para el manejo de la diabetes tipo 2.
Área de la Ciencia:
- Endocrinología Endocrinología.
- Enfermedades Metabólicas Las enfermedades metabólicas.
Sus antecedentes:
- El péptido 1 parecido al glucagón (GLP-1) es un agente terapéutico potencial para la diabetes tipo 2.
- Los efectos a largo plazo de la administración continua de GLP-1 requieren investigación.
Objetivo del estudio:
- Para evaluar los efectos de 6 semanas de infusión continua subcutánea de GLP-1 en pacientes con diabetes tipo 2.
- Evaluar el impacto de la GLP-1 en el control glucémico, la función de las células beta, la sensibilidad a la insulina y otros parámetros metabólicos.
Principales métodos:
- Un estudio piloto aleatorizado y controlado con placebo de 6 semanas en el que participaron 20 pacientes con diabetes tipo 2.
- Los pacientes recibieron infusión subcutánea continua de GLP-1 (n=10) o solución salina (n=10).
- Las evaluaciones incluyeron perfiles glucémicos, pruebas de función de las células beta, mediciones de sensibilidad a la insulina y calificaciones de apetito.
Principales resultados:
- La infusión de GLP-1 redujo significativamente los niveles de glucosa plasmática, HbA1c y fructosamina.
- Mejoras observadas en la sensibilidad a la insulina y la función de las células beta.
- Se observaron niveles reducidos de ácidos grasos libres, vaciamiento gástrico inhibido, disminución del peso corporal y disminución del apetito con el tratamiento con GLP-1.
Conclusiones:
- La administración continua de GLP-1 demuestra un potencial terapéutico significativo para la diabetes tipo 2.
- Se necesita más investigación para explorar la eficacia y seguridad a largo plazo de los tratamientos con GLP-1.
Videos de Conceptos Relacionados
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...